Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study

JAMA

Volumn 297, Issue 14, 2007, Pages 1551-1561

  Morgan, Thomas M ^a,c   Krumholz, Harlan M ^a   Lifton, Richard P ^a   Spertus, John A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL RESEARCH; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; CASE CONTROL STUDY; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; HEART INFARCTION; MONTE CARLO METHOD; REPRODUCIBILITY; REVIEW; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MONTE CARLO METHOD; MYOCARDIAL INFARCTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 34247144499     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.14.1551     Document Type: Article

References (110)

1. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-1046.
2. Scheuner MT. Clinical application of genetic risk assessment strategies for coronary artery disease: genotypes, phenotypes, and family history. Prim Care. 2004; 31:711-737, xi-xii.
3. Casas JPCJ, Miller GJ, Hingorani AD, Humphries SE. Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet. 2006; 70:145-169.
4. Morgan TM, Coffey CS, Krumholz HM. Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. Clin Genet. 2003;64:7-17.
5. Yamada Y. Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke. Circ J. 2006;70:1240-1248.
6. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309.
7. The International HapMap Consortium. The International HapMap Project. Nature. 2003;426:789-796.
8. Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM Jr, Marian AJ. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001;88:969-973.
9. Zwarts KY, Clee SM, Zwinderman AH, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61:115-125.
10. Clee SM, Zwinderman AH, Engert JC, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 2001;103:1198-1205.
11. Tregouet DA, Ricard S, Nicaud V, et al. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler Thromb Vasc Biol. 2004;24:775-781.
12. Tobin MD, Braund PS, Burton PR, et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J. 2004;25:459-467.
13. Zee RY, Cook NR, Reynolds R, Cheng S, Ridker PM. Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans. Genetics. 2005;169:1583-1587.
14. Higashi K, Ishikawa T, Ito T, Yonemura A, Shige H, Nakamura H. Association of a genetic variation in the beta 3-adrenergic receptor gene with coronary heart disease among Japanese. Biochem Biophys Res Commun. 1997;232:728-730.
15. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 2003;23:1269-1275.
16. Fatini C, Abbate R, Pepe G, et al. Searching for a better assessment of the individual coronary risk profile: the role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J. 2000;21:633-638.
17. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
18. Wang XL, Liu SX, McCredie RM, Wilcken DE. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest. 1996;98:372-377.
19. Reguero JR, Cubero GI, Batalla A, et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease. Cardiology. 1998;90:231-235.
20. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16:1250-1255.
21. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet. 2000;9:57-61.
22. Aoki S, Mukae S, Itoh S, et al. The genetic factor in acute myocardial infarction with hypertension. Jpn Circ J. 2001;65:621-626.
23. Zee RY, Cook NR, Cheng S, et al. Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis. 2004;175:91-94.
24. Ortlepp JR, Vesper K, Mevissen V, et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med. 2003;81:363-367.
25. González P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001;2:191-195.
26. Hubacek JA, Rothe G, Pit'ha J, et al. C(?260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 1999;99:3218-3220.
27. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al; the Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338: 86-93.
28. Klerkx AH, Tanck MW, Kastelein JJ, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked ?629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet. 2003;12:111-123.
29. Eriksson AL, Skrtic S, Niklason A, et al. Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population. Eur Heart J. 2004;25:386-391.
30. Niessner A, Marculescu R, Haschemi A, et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome: a possible implication of fractalkine in inflammatory activation. Thromb Haemost. 2005; 93:949-954.
31. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001; 89:401-407.
32. Patel S, Steeds R, Channer K, Samani NJ. Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens. 2000; 13:134-139.
33. Hautanen A, Toivanen P, Manttari M, et al. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation. 1999;100:2213-2218.
34. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003;13:715-720.
35. Funk M, Endler G, Freitag R, et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem. 2004;50:2395-2398.
36. Endler G, Mannhalter C, Sunder-Plassmann H, et al. The K121Q polymorphism in the plasma cell membrane glycoprotein 1 gene predisposes to early myocardial infarction. J Mol Med. 2002;80:791-795.
37. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004;291:2969-2977.
38. Shearman AM, Cupples LA, Demissie S, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA. 2003;290: 2263-2270.
39. Endler G, Mannhalter C, Sunder-Plassmann H, et al. Homozygosity for the C→T polymorphism at nucleotide 46 in the 5′ untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol. 2001;115:1007-1009.
40. Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta. 2003;330:31-55.
41. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997; 90:1747-1750.
42. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774-780.
43. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104:3063-3068.
44. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347: 1916-1923.
45. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis. 2002;13:13-19.
46. Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibalpha gene ?5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart. 2002;87:70-74.
47. Lin RC, Wang XL, Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension. 2003;41:404-407.
48. Hetet G, Elbaz A, Gariepy J, et al. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest. 2001;31:382-388.
49. Yamada S, Akita H, Kanazawa K, et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis. 2000;150:143-148.
50. Jiang H, Klein RM, Niederacher D, et al. C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, codon 469): a risk factor for coronary heart disease and myocardial infarction. Int J Cardiol. 2002; 84:171-177.
51. Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J Am Coll Cardiol. 2001;38:712-717.
52. Georges JL, Loukaci V, Poirier O, et al; Etude Cas-Temoin de l'Infarctus du Myocarde. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. J Mol Med. 2001;79:300-305.
53. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the ?174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22:2066-2071.
54. Baroni MG, D'Andrea MP, Montali A, et al. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:2975-2980.
55. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999;93:2449-2453.
56. Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis. 2003;14:65-79.
57. Zambon A, Deeb SS, Pauletto P, Crepaldi G, Brunzell JD. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol. 2003;14:179-189.
58. Ji J, Herbison CE, Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM. Hepatic lipase gene ?514 C/T polymorphism and premature coronary heart disease. J Cardiovasc Risk. 2002;9:105-113.
59. Hokanson JE. Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr Opin Lipidol. 1999;10:393-399.
60. Schulz S, Schagdarsurengin U, Greiser P, et al. The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis-novel genomic variants and functional consequences. Hum Mutat. 2002;20:404.
61. PROCARDIS Consortium. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet. 2004;12:770-774.
62. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002; 32:650-654.
63. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386-2393.
64. Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet. 2002;66:343-352.
65. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002;40:43-48.
66. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031.
67. Ledmyr H, McMahon AD, Ehrenborg E, et al. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation. 2004;109:2279-2284.
68. Juo SH, Han Z, Smith JD, Colangelo L, Liu K. Common polymorphism in promoter of microsomal triglyceride transfer protein gene influences cholesterol, ApoB, and triglyceride levels in young African American men: results from the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol. 2000;20:1316-1322.
69. Hyndman ME, Bridge PJ, Warnica JW, Fick G, Parsons HG. Effect of heterozygosity for the methionine synthase 2756 A→G mutation on the risk for recurrent cardiovascular events. Am J Cardiol. 2000;86: 1144-1146, A1149.
70. Gruchala M, Ciecwierz D, Wasag B, et al. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J. 2003;145: 125-131.
71. Tatsuguchi M, Furutani M, Hinagata J, et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun. 2003;303:247-250.
72. Gardemann A, Mages P, Katz N, Tillmanns H, Haberbosch W. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis. 1999;145:315-323.
73. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22-phox gene in patients with coronary artery disease. Circulation. 1998;97:135-137.
74. Wenzel K, Baumann G, Felix SB. The homozygous combination of Leu125Val and Ser563Asn polymorphisms in the PECAM1 (CD31) gene is associated with early severe coronary heart disease. Hum Mutat. 1999;14:545.
75. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart. 2002;87:107-112.
76. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
77. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62:36-44.
78. Ridker PM, Cook NR, Cheng S, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:859-863.
79. Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA. 2004;291:2221-2228.
80. Ye L, Miki T, Nakura J, et al. Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population. Am J Med Genet. 1997;68:494-498.
81. Herrmann SM, Ricard S, Nicaud V, et al. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet. 1998;7:1277-1284.
82. Moatti D, Seknadji P, Galand C, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol. 1999;19:862-869.
83. Chao TH, Li YH, Chen JH, et al. Relation of thrombomodulin gene polymorphisms to acute myocardial infarction in patients
84. Doggen CJ, Kunz G, Rosendaal FR, et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost. 1998;80:743-748.
85. Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H. Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation. 2001;103:1386-1389.
86. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104: 2641-2644.
87. Boekholdt SM, Trip MD, Peters RJ, et al. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2002;22:e24-e27.
88. Webb KE, Martin JF, Hamsten A, et al. Polymorphisms in the thrombopoietin gene are associated with risk of myocardial infarction at a young age. Atherosclerosis. 2001;154:703-711.
89. Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J. 2004;148:1034-1040.
90. Padovani JC, Pazin-Filho A, Simoes MV, Marin-Neto JA, Zago MA, Franco RF. Gene polymorphisms in the TNF locus and the risk of myocardial infarction. Thromb Res. 2000;100:263-269.
91. Poirier O, Nicaud V, Gariepy J, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness-the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet. 2004;12:213-219.
92. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
93. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410-414.
94. Yan J, Feng J, Hosono S, Sommer SS. Assessment of multiple displacement amplification in molecular epidemiology. Biotechniques. 2004;37: 136-138, 140-133.
95. Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A. 2002;99:5261-5266.
96. Jurinke C, van den Boom D, Cantor CR, Koster H. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol. 2002;77:57-74.
97. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol. 2004;26: 147-164.
98. Chiodini BD, Barlera S, Franzosi MG, Beceiro VL, Introna M, Tognoni G. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis. 2003;167:355-366.
99. González-Conejero R, Corral J, Roldan V, et al. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood. 2002; 100:2081-2086.
100. Hines LM, Stampfer MJ, Ma J, et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med. 2001;344:549-555.
101. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 2005;76:449-462.
102. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
103. Gauderman WJ. Candidate gene association analysis for a quantitative trait, using parent-offspring trios. Genet Epidemiol. 2003;25:327-338.
104. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002;21:35-50.
105. Weng L, Kavaslar N, Ustaszewska A, et al. Lack of MEF2A mutations in coronary artery disease. J Clin Invest. 2005;115:1016-1020.
106. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis. 2003; 166:323-329.
107. Freely associating. Nat Genet. 1999;22:1-2.
108. Salanti G, Sanderson S, Higgins JP. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med. 2005;7:13-20.
109. Marchini J, Cardon LR, Phillips MS, Donnelly P. The effects of human population structure on large genetic association studies. Nat Genet. 2004;36:512-517.
110. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.